Hereditary hemochromatosis diagnostic markers and diagnostic methods
Patent 5712098 Issued on January 27, 1998. Estimated Expiration Date: April 16, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
435/6, Involving nucleic acid536/23.5, Encodes an animal polypeptide536/24.3Probes for detection of specific nucleotide sequences or primers for the synthesis of DNA or RNA
A single base-pair polymorphism involving a mutation from Guanine (G), in individuals unaffected by the hereditary hemochromatosis (HH) gene defect, to Adeninc (A), in individuals affected by the HH gene defect is disclosed. The presence or absence of the polymorphic allele is highly predictive of whether an individual is at risk from HH: the polymorphism is present in 82% of affected individuals and only 4% of a random population screen. Methods of diagnosis, markers, and primers are disclosed and claimed in accordance with the present invention.
Other References
Jazwinska and Powell Hemochromatosis and "HLA-H": definite| Hepatology. vol. 25(2):495-496, Feb. 1997
Feder, et. al.. A novel MHC class I-like gene is mutated in patients with a hereditary haemochromatosis. Naure Genetics. vol. 13:399-408, Aug. 1996
Bacon, B.R., "Causes of Iron Overload," N. Eng. J. Med. 326(2):126-127 (1992)
Cartwright, G.E. et al., "Inheritance of Hemochromatosis: Linkage to HLA," Trans. Assoc. Am. Phys. 91:273-281 (1978)
Edwards, C.Q. et al., "Screening for Hemochromatosis," N. Eng. J. Med. 328(22):1616-1619 (1993)
Finch, C.A., "Hemochromatosis--Treatment is Easy, Diagnosis Hard," West. J. Med. 153(3):323-325 (19980)
Gyapay, G. et al., "The 1993-94 Genethon human genetic linkage map," Nature Genetics 7:246-338 (1994)
Jazwinska, E.C. et al., "Localization of the Hemochromatosis Gene Close to D6S105," Am. J. Hum. Genet. 53:347-352 (1993)
Jazwinska, E.C. et al., "Haplotype Analysis oin Australian Hemochromatosis Patients: Evidence for a Predominant Ancestral Haplotype Exclusively Associated Hemochromatosis," Am. J. Hum. Genet. 56:428-433 (1995)
Lipinski, M. et al., "Idiopathic Hemochromatosis: Linkage with HLA," Tissue Antigens 11:471-474 (1978)
Lovett, M. et al., "Direct selection: A method for the isolation of cDNAs encoded by large genomic regions," Proc Natl. Acad. Sci. U.S.A. 88:9628-9632 (1991)
Nikiforov, T.T. et al., "Genetic Bit Analysis: a solid phase method for typing single nucleotide polymorphisms," Nucl. Acids Res. 22(20):4167-4175 (1994)
Phatak, P.D. et al., "Cost-effectiveness of Sceening for Hereditary Hemochromatosis," Arch. Intern Med. 154:769-776 (1994)
Simon,M. et al., "A Stody of 609 HLA Haplotypes Marking for the Hemochromatosis Gene: (1) Mapping of the Gene near the HLA-A Locus and Characters Required to Define a heterozygous Population and (2) Hypothesis Concerning the Underlying Cause of Hemochromatosis-HLA Association," Am. J. Hum. Genet. 41:89-105 (1987)
Stone, C. et al., "Isolation of CA dinucleotide repeats close to D6S105; linkage disequilibrium with haemochromatosis," Hum. Molec. Genet. 3(11):2043-2046 (1994)
Summers, K.M. et al., "HLA Determinants in an Australian Population of Hemochromatosis Patients and Their Families," Am. J. Hum. Genet. 45:41-48 (1989)
Worwood, M. et al., "Alleles at D6S265 and D6S105 define a haemochromatosis-specific genotype," Br. J. Haemat. 86:863-866 (1994
April 16, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
